Wegovy comparison and guidance in the UK
A detailed UK guide to Wegovy use: how the FlexTouch pen works, how to inject correctly, what each dose is for, how dose escalation usually happens, what to do if you miss a dose, how storage works, and which symptoms need urgent medical advice.
Last Updated: 18 April 2026 | Primary Sources: UK Wegovy leaflet, SmPC and MHRA updates | Questions? info@wegocompare.co.uk
Wegovy is a once-weekly injection containing semaglutide. In the UK it is used alongside a reduced-calorie diet and increased physical activity for weight management in adults with obesity, in adults who are overweight with weight-related health problems, and in adolescents aged 12 years and above with obesity and body weight above 60kg.
UK prescribing information also includes a cardiovascular risk-reduction indication in certain adults with established cardiovascular disease and BMI of 27 or above. For adolescents, treatment continuation is reassessed after time on the 2.4mg dose or maximum tolerated dose.
In the UK, Wegovy treatment usually starts at 0.25mg once weekly and is increased every 4 weeks to 0.5mg, 1mg, 1.7mg and then 2.4mg. The purpose of this gradual escalation is to improve tolerability, especially gastrointestinal tolerability, rather than to rush treatment.
If clinically needed, some adults with obesity may then be increased from 2.4mg to 7.2mg once weekly after at least 4 weeks on 2.4mg, but that is a prescriber-led higher-dose option rather than the standard path for most users.
| Weeks | Weekly dose | Main role | What matters most |
|---|---|---|---|
| 1–4 | 0.25mg | Starter dose | Settling in and learning correct weekly use |
| 5–8 | 0.5mg | Early escalation | Assess appetite change and tolerability |
| 9–12 | 1mg | Mid escalation | Consistency, hydration and food quality |
| 13–16 | 1.7mg | Late escalation | Whether side effects remain manageable |
| 17+ | 2.4mg | Standard maintenance | Long-term adherence and sustainable routine |
| Selected adults only | 7.2mg | Higher-dose option | Strict prescriber instruction only |
What it is for: 0.25mg is the standard starting dose. It is not designed to be the full long-term treatment dose. Its main purpose is to help the body begin adapting to semaglutide before larger weekly doses are introduced.
When it is usually used: this dose is usually used for weeks 1 to 4. During this stage, the most important task is not maximum fat loss but building a repeatable routine: correct injection technique, a fixed weekly dosing day, regular fluids, and meals that are less likely to worsen nausea.
What people often notice: some people already feel less hungry at 0.25mg, but others notice only a modest effect. That does not mean treatment is failing. Early response varies, and the standard treatment plan expects escalation after 4 weeks if the dose is tolerated.
What it is for: 0.5mg is the usual second step in the standard escalation schedule. It increases exposure after the starter phase while still remaining below the later maintenance range.
When it is usually used: this dose is usually used for weeks 5 to 8. By this point, many people begin to judge whether appetite suppression is becoming more reliable from week to week, and whether the treatment routine is sustainable.
What people often notice: hunger control may become more obvious here than it was on 0.25mg. Some users notice fewer cravings, a longer feeling of fullness, and an easier time keeping portions smaller. Others still need more time or later escalation before those effects become clear.
What it is for: 1mg is the middle stage of the standard UK escalation pathway. It sits between early build-up dosing and the later higher-strength phases used before maintenance.
When it is usually used: this dose is usually used for weeks 9 to 12. It is often a practical checkpoint dose because enough time has passed to judge adherence, eating structure, hydration habits, bowel tolerance, and whether the weekly schedule is actually being maintained without drift.
What people often notice: for many users, this is a stage where the treatment feels more established rather than experimental. Fullness may last longer, snacking pressure may reduce, and weekly behaviour patterns can become easier to control if food choices and routine are reasonably stable.
What it is for: 1.7mg is the fourth standard step before the usual 2.4mg maintenance dose. It is a higher-intensity escalation stage intended to bridge users toward standard long-term dosing.
When it is usually used: this dose is usually used for weeks 13 to 16. At this stage, the question is less whether Wegovy is doing anything and more whether the treatment remains tolerable enough to keep building toward maintenance.
Why this dose matters clinically: some adults remain on 1.7mg if 2.4mg is not tolerated. That makes 1.7mg more than just a stepping stone. It can also be a meaningful ongoing dose level when the standard higher maintenance dose is not suitable for the individual.
What it is for: 2.4mg is the standard maintenance dose in the usual Wegovy pathway. Once reached and tolerated, it is the routine long-term target dose for many adult users.
When it is usually used: this dose is usually reached from week 17 onward after gradual escalation. It is the point where the treatment plan should feel sustainable rather than provisional. Weekly adherence, food quality, hydration and side-effect management all need to be stable enough for longer-term use.
Important practical point: 2.4mg is the standard maintenance dose, but it is not a competition target. A higher dose is only useful if it remains tolerable. The schedule is designed to get users to an effective maintenance dose gradually, not to force everyone to escalate aggressively regardless of side effects.
What it is: 7.2mg is now a UK Wegovy higher-dose option for selected adults, but it is not part of the standard starter-to-maintenance pathway used for most users. It is a later higher-dose option considered only after at least 4 weeks on 2.4mg and only if specifically prescribed.
Why this section needs care: early 2026 MHRA and SmPC wording described the higher weekly 7.2mg dose as being delivered through three 2.4mg injections on the same day, while April 2026 MHRA news also announced approval of a new single-dose 7.2mg pen for adult patients with obesity. That means users should never improvise this dose or copy older instructions without checking the exact product and current prescriber directions.
What matters in practice: this is not a routine next step for everyone at 2.4mg, not a self-adjustment option, and not something to recreate independently by combining pens or doses.
The most common problems early on are nausea, vomiting, diarrhoea, constipation and stomach discomfort. Dehydration is one of the most important practical risks if vomiting or diarrhoea become significant.
These expanded answers are written to work as stronger standalone information sections and better internal-link targets across your guides and comparison pages.
Usually yes. The standard rule is that there should be at least 3 days between two doses. After changing the day, continue weekly on the new day.
This matters most if you are trying to tighten routine, reduce missed doses, or move injections to a quieter day because side effects are stronger in the first 24 to 48 hours. Read the timing section above for the practical rule: missed dose and timing guidance.
If the missed dose is remembered within 5 days, take it as soon as possible. If more than 5 days have passed, skip that dose and wait until your normal weekly day.
Do not double up doses to catch up. If you have missed multiple weeks, the safest next step is to ask your prescriber whether you should restart more cautiously. The full rule is covered here: Wegovy missed dose rules.
After first use, the pen can be kept below 30°C for up to 6 weeks. It can also be kept in the fridge. It should not be frozen, and it should not be stored with a needle attached.
This becomes especially important during travel, hot weather, and commuting. If the pen has been exposed to high heat, it is better to ask your pharmacy what to do than to assume it is fine. Read the full section here: Wegovy storage and travel.
Yes. A new sterile needle should be used for every injection, and the needle should be removed immediately after use. Leaving a needle attached between doses can cause leakage, blockage, contamination, or inaccurate dosing.
If technique feels uncertain, return to the step-by-step injection section here: how to inject Wegovy correctly.
For many adults, 2.4mg once weekly is the standard maintenance dose. That does not mean every user must push to it at the same speed. Some people stay longer at lower stages, and some remain on 1.7mg if 2.4mg is not well tolerated.
The most useful anchor section for that is here: 2.4mg Wegovy maintenance dose. If you need the full path from starter dose onward, use the full Wegovy dose schedule.
Not necessarily. 0.25mg is mainly a starter dose designed to improve tolerability while your body adjusts to semaglutide. Some users notice reduced appetite early, but others feel only a limited effect at first.
The key point is that 0.25mg is not usually the long-term target dose. Read the full section here: 0.25mg Wegovy starter dose.
1.7mg is usually a late-escalation dose used before standard maintenance, while 2.4mg is the standard maintenance dose for many adults. The practical difference is not just strength. It is also about whether side effects remain manageable and whether the user is ready for long-term routine at a higher level.
Compare the two sections directly here: 1.7mg Wegovy and 2.4mg Wegovy.
No. It is a higher-dose option for selected adults if specifically prescribed. It should not be treated as the normal next step for routine users who reach 2.4mg.
Because the UK position changed during 2026, this section should be read carefully and updated when product format changes are reflected in the leaflet or prescribing workflow. Use this anchor for the dedicated section: 7.2mg Wegovy explained.
The highest-value basics are smaller meals, slower eating, consistent hydration, less greasy food during rough patches, and avoiding alcohol if it makes symptoms worse. If vomiting or diarrhoea become persistent, dehydration becomes the real risk rather than simple discomfort.
Read the prevention section here: side-effect reduction and hydration. If symptoms are severe, check when to get urgent help.
Check current provider pricing for your prescribed Wegovy strength and compare practical differences before you proceed.
